As the Australian market winds down for the holiday season, with a slight dip attributed to profit-taking and global indices nearing record highs, investors are reflecting on their portfolios and considering new opportunities for growth. In such an environment, stocks with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the company best.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Wisr (ASX:WZR) 10.2% 96.3% Titomic (ASX:TTT) 14.8% 74.9% Sea Forest (ASX:SEA) 15.1% 92.6% Pointerra (ASX:3DP) 19.8% 110.3% Newfield Resources (ASX:NWF) 31.5% 72.1% Lunnon Metals (ASX:LM8) 11% 31.4% Emerald Resources (ASX:EMR) 18.4% 43% Echo IQ (ASX:EIQ) 19% 51.4% BlinkLab (ASX:BB1) 35.3% 101.4% Adveritas (ASX:AV1) 18.4% 96.8%

Click here to see the full list of 112 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

PolyNovo

Simply Wall St Growth Rating: ★★★★★☆

Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices across several countries including Australia, New Zealand, the United States, and the United Kingdom, with a market cap of A$887.73 million.

Operations: The company's revenue is derived from the development, manufacturing, and commercialisation of the NovoSorb Technology, amounting to A$128.70 million.

Insider Ownership: 10.4%

Earnings Growth Forecast: 27.4% p.a.

PolyNovo is poised for significant growth, with earnings projected to rise 27.4% annually, outpacing the Australian market. Revenue is also expected to grow faster than the market at 14.8% per year. The stock trades at nearly 20% below its estimated fair value, suggesting potential undervaluation. Recent board appointments of experienced executives like Amy Demediuk and Robert Douglas bolster governance and strategic capabilities, enhancing PolyNovo's prospects in the healthcare sector.

Delve into the full analysis future growth report here for a deeper understanding of PolyNovo. Our valuation report unveils the possibility PolyNovo's shares may be trading at a premium.ASX:PNV Ownership Breakdown as at Dec 2025

PYC Therapeutics

Simply Wall St Growth Rating: ★★★★☆☆

Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics for genetic diseases, with a market cap of A$991.54 million.

Operations: The company generates revenue of A$23.49 million from its activities in discovering and developing RNA therapeutics for genetic diseases.

Insider Ownership: 38.3%

Lire la suite

Earnings Growth Forecast: 27.6% p.a.

PYC Therapeutics is undergoing significant changes, with Peter Coleman appointed as Independent Non-Executive Chair, bringing expertise in mergers and acquisitions. Despite forecasts of a 5.8% annual revenue decline over the next three years, PYC's earnings are expected to grow at 27.62% annually and achieve profitability above market averages within the same period. Insider confidence remains high with recent substantial share purchases, although shareholders experienced dilution last year. The stock trades significantly below its estimated fair value.

Get an in-depth perspective on PYC Therapeutics' performance by reading our analyst estimates report here. Our comprehensive valuation report raises the possibility that PYC Therapeutics is priced higher than what may be justified by its financials.ASX:PYC Ownership Breakdown as at Dec 2025

Universal Store Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Universal Store Holdings Limited operates in the Australian fashion retail market and has a market cap of A$625.27 million.

Operations: The company's revenue is primarily derived from two segments: CTC, contributing A$40.06 million, and US & PS, generating A$306.41 million.

Insider Ownership: 12.7%

Earnings Growth Forecast: 16.8% p.a.

Universal Store Holdings is poised for growth with earnings expected to increase by 16.8% annually, outpacing the broader Australian market. Revenue growth is also forecasted to exceed market averages at 8.1% per year, though not reaching high-growth thresholds. Despite a dividend yield of 4.72% not being well-covered by earnings, the stock trades significantly below its estimated fair value and analysts predict a price rise of 25.2%. Return on equity is projected to be robust at 28.4%.

Unlock comprehensive insights into our analysis of Universal Store Holdings stock in this growth report. Our valuation report unveils the possibility Universal Store Holdings' shares may be trading at a discount.ASX:UNI Ownership Breakdown as at Dec 2025

Make It Happen

Delve into our full catalog of 112 Fast Growing ASX Companies With High Insider Ownership here. Interested In Other Possibilities? AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:PNV ASX:PYC and ASX:UNI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Afficher les commentaires